Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. - Wikidata - awgldk - TriplyDB

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

http://www.wikidata.org/entity/Q40053132

about

Ion channels as drug targets in central nervous system disorders Glutamate receptor ion channels: structure, regulation, and function Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.A series of structurally novel heterotricyclic alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor-selective antagonists.Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease.Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects.Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.Variations in the stimulus salience of cocaine reward influences drug-associated contextual memory Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential Glutamate receptors as therapeutic targets for Parkinson's disease.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Animal models of Parkinson's disease: a gateway to therapeutics?Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Mavoglurant as a treatment for Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Translational psychiatry--light at the end of the tunnel.Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients.Metabotropic glutamate receptors for Parkinson's disease therapy.Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model.NMDA Receptors in the Central Nervous System.Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.Diminution of the NMDA receptor NR2B subunit in cortical and subcortical areas of WAG/Rij rats.

P2860

Q27004533-E04E1146-DE62-47C8-B40C-EC05EB3F0436 Q28290774-94E3CD43-8737-43F0-A123-3DB9DCD695BD Q28542729-5EB725AD-3C72-42D1-AECB-1953375356CF Q30830257-8D078338-FF8C-4BCC-B5A5-F588F0D36791 Q33428476-D205A593-2485-43C1-888A-C0BD875DE1BB Q33834247-B9054E50-FA07-4353-95E7-0641C3EC10B6 Q34124829-EFF2999B-481C-4926-911F-22CE1AE08384 Q34126315-C94060F0-8CAF-4313-8F70-45252B785BB9 Q35124773-CA8B6CE0-FAF9-4173-B7B6-F9D62B2B7384 Q35202428-BEF63BCD-C2B4-4CEF-9353-0F081462E301 Q35492255-A44CC1AD-35BC-4274-9E95-110E0764EBBC Q35547363-BCDE677A-93A2-4D6D-B781-5A0DBC4B81FF Q36798980-C4B433D6-8352-46B6-8447-EA084DA4832F Q36799584-29451984-309B-4EE2-BE6C-54AD16E2D922 Q37001159-2756540C-C1AE-4706-B8F8-09984BB1A652 Q37220392-844EA3CA-F30E-4863-B6A8-C775C970755C Q37506507-3332C1EF-E05F-4354-AEA4-0B00B16BC413 Q37548763-22AD5EE4-D643-4174-9337-8D4D9E8E3A1A Q37585401-4B211B75-0976-4E60-B86B-331AC17A38C0 Q37924629-928D16E8-5537-4470-9DA7-3365BD02FC63 Q37974709-4FD6366B-32BE-4AA1-A355-A9EC39D572B4 Q38056852-09537BFA-99B9-44EC-8D29-DA3BB256A850 Q38155480-1F36A392-E9DF-40CD-8661-2CD05BCFA6E2 Q38156760-C1F44BA0-F445-4C10-BA16-5BFA6E6324E1 Q38174986-6092A115-4D90-4FFB-A7FB-88E63FE2E6D7 Q38190016-7D0C8B61-F537-47E1-B397-52B89C4231F4 Q38222814-BD3D8052-C4BA-4915-AC3A-A0FAAA4C153C Q38262418-ED12ED32-779E-4BB9-BE94-1FE048A0AAEE Q38370696-2E39131C-995E-4915-9A68-1F02A4309303 Q38602173-EF41F76F-2CD1-46F5-A437-C80C91EB26AB Q38658203-A70D80BC-630F-4B1C-9682-1C00FFBD1BEE Q38811387-E267135A-58DD-406C-B913-BEDF295716EA Q39324877-2571880A-3D35-46D5-B9D8-E864944F1F56 Q40789803-8E6F8B06-C5B4-405E-831F-9FDCE8F405D2 Q41420806-D0C1A05A-682D-4D8F-8E09-09ECB1C569DE Q41818450-D0BD6E45-63EA-4632-9950-5F267319B7B8 Q41911647-3D307260-E388-455B-B2AA-A1E2346AF6CA Q48029905-8C3A1C33-45A9-47EB-BF2C-1304A15F43C1 Q48631361-5A82EF06-620B-45A3-A2F8-BB2969558783 Q50919849-709D585D-825F-4D6B-B001-8F47D80B497E

P2860

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

http://www.wikidata.org/entity/Q40053132

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Effects of a NR2B selective NM ...... n dyskinesia and Parkinsonism.

@en

type

label

Effects of a NR2B selective NM ...... n dyskinesia and Parkinsonism.

@en

prefLabel

Effects of a NR2B selective NM ...... n dyskinesia and Parkinsonism.

@en

P1433

Q40053132-3A2885AA-3B8B-41BD-A227-B6C75C6C3F59

P1476

Q40053132-D5C8E626-EC24-4585-BEC9-886334714565

P2093

Q40053132-1B56EA34-5CE8-463F-A8A2-F96B04B1D011

Q40053132-260B2CF7-604F-4BBF-A5D4-A5A59D52B0DF

Q40053132-5A077634-760F-43FB-AFBF-B11A5EC270C8

Q40053132-C01DD470-55AE-41D8-A132-783779EB927A

Q40053132-C67564CB-7460-4D2B-B1B4-28D25E0262BB

Q40053132-DD8C4F21-D89A-4C3E-A412-2206C13CE837

Q40053132-EE793947-182C-4072-8108-74C21C392426

P2860

Q40053132-0379F1DC-85FA-4580-93BC-8F4DEA0F69AD

Q40053132-134DBDC5-04C4-432E-9844-49C1CE4B201D

Q40053132-15194B78-BF82-441F-9839-C72264A0AA45

Q40053132-1B197D84-83E0-4728-B207-2F1794302653

Q40053132-23D71B54-D841-4282-A56F-BCCC260448FD

Q40053132-23FB6872-276B-4D9F-B9D8-CD1AC69083F1

Q40053132-25F89A2B-DABA-42EF-ABBF-7CA05902E7BD

Q40053132-2F4BC744-8948-4ECB-88D5-0FE039F1412C

Q40053132-30BD5F7F-39BE-48C6-B8A8-797965B17DBF

Q40053132-39912B57-0175-41BA-AEB5-0F4EFEC94243

P304

Q40053132-CD377FE6-6683-427A-A7D3-45F3428F3668

P31

Q40053132-8915F14B-05EE-4F3A-A7B9-E6A12EDA04D7

P356

Q40053132-73FCB9F2-56E4-403B-A842-68BBD146ACAA

P407

Q40053132-0F549D4A-676F-49F4-B6A9-0A4DC5FF9361

P433

Q40053132-10944074-1C16-405C-BB4B-0D077CB35313

P478

Q40053132-FCBA4175-E87C-426E-BE52-B141A650B05D

P50

Q40053132-8C8EDCA2-EC20-477B-9A0D-7A6AE134E69B

Q40053132-8FB77D60-3FF1-4756-8D17-E649E9961C2D

P577

Q40053132-B3EE2B4F-6CEC-48C6-8DFD-82E6E9E36734

P5875

Q40053132-A9D6674C-0612-42E4-896F-E806AA66290A

P698

Q40053132-FCF7299E-BC65-4944-9525-2F95F019CC12

P921

Q40053132-4857D33B-5ABF-48F3-9156-66260DB80312

Q40053132-C41073DF-DF1C-4107-89F0-1CE139436C7A

P932

Q40053132-9A604747-389C-4417-951B-CD074B12D8F6

P356

P1433

Movement Disorders

P1476

Effects of a NR2B selective NM ...... on dyskinesia and Parkinsonism

@en

P2093

Brenda Jamerson

http://www.w3.org/2001/XMLSchema#string

Jaren W Landen

http://www.w3.org/2001/XMLSchema#string

Jerry L Weaver

http://www.w3.org/2001/XMLSchema#string

John G Nutt

http://www.w3.org/2001/XMLSchema#string

Michael Krams

http://www.w3.org/2001/XMLSchema#string

Penelope Hogarth

http://www.w3.org/2001/XMLSchema#string

Trish Kirchhoff

http://www.w3.org/2001/XMLSchema#string

P2860

Glutamate as a neurotransmitter in the brain: review of physiology and pathology

NMDA receptor regulation of memory and behavior in humans

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury.

Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.

CP-101606 Pfizer Inc.

NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats.

(1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses.

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.

P304

1860-1866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.22169

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Frank S. Menniti

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23225676

http://www.w3.org/2001/XMLSchema#string

P698

18759356

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3390310

http://www.w3.org/2001/XMLSchema#string